As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
We are currently accepting submissions to a new cross-journal series, The Microbiota-Gut-Brain Axis.
In partnership with twelve other BMC journals, this series will bring together human and animal studies covering all aspects of the axis' role in health and disease, including Alzheimer's.
In partnership with Research Square, Alzheimer's Research & Therapy is now offering In Review. Authors choosing this free optional service will be able to:
Read more about the full range of benefits of In Review and how to opt in, or see the In Review platform for yourself here.
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Alzheimer's Research & Therapy is proudly affiliated with Alzheimer's Research UK and Alzheimer's Disease International.
Speed
56 days to first decision for reviewed manuscripts only
32 days to first decision for all manuscripts
128 days from submission to acceptance
25 days from acceptance to publication
Citation Impact
6.116 - 2-year Impact Factor
7.114 - 5-year Impact Factor
1.546 - Source Normalized Impact per Paper (SNIP)
2.298 - SCImago Journal Rank (SJR)
Usage
657,918 downloads
1,172 Altmetric mentions
Alzheimer's Research & Therapy
